TRISALUS LIFE SCIENCES - Key Persons
Job Titles:
- Member of the Audit Committee
- Member of the Nominating and Corporate Governance Committee
- Member of the Nominating and Corporate Governance Committee Member of the Science and Technology Committee
- Member of the Science and Technology Committee
- President and Founder of Samaritan Health Initiatives, Inc
Dr. Andrew von Eschenbach is the President and founder of Samaritan Health Initiatives, Inc., a health care policy consultancy, a role which he has held since 2010. He is also an Adjunct Professor at the University of Texas M.D. Anderson Cancer Center ("MDACC"), a position he has held since 2009.
Dr. von Eschenbach holds advisory roles as the Senior Advisor at Target RWE, a biotechnology company, since September 2020, and Medical Advisor at Datavant, a health information technology company, since January 2020. From October 2017 to June 2019, Dr. von Eschenbach served as Chief Medical Advisor at Malin Corporation PLC, a life sciences company. From 2009 to 2021, he worked on the International Advisory Council of Chugai Pharmaceutical Co., Ltd., a Japanese drug manufacturer. From 2012 to 2016, Dr. von Eschenbach was a Senior Fellow and Director of the FDA Project at the Manhattan Institute, a think tank. From 2009 to 2018, he served on the GE Healthymagination Advisory Board, a GE Healthcare initiative to provide better healthcare for more people around the world. From 2012 to 2016, he served as a global council member of Eli Lilly and Company, PACE, a global collaboration that encourages public policies and healthcare decisions that speed the development of new medicines. From September 2005 to January 2009, Dr. von Eschenbach served as Commissioner of the FDA. Previously, Dr. von Eschenbach served as Director of the National Cancer Institute at the National Institutes of Health from January 2002 to June 2006. As a researcher, clinician and administrator, Dr. von Eschenbach served in a variety of roles at MDACC, including as Director, Genitourinary Cancer Center, Vice President for Academic Affairs, and Executive Vice President and Chief Academic Officer. Dr. von Eschenbach currently serves on the boards of directors of Bausch and Lomb Corporation and Celularity, Inc. In addition, Dr. von Eschenbach previously served on the boards of directors of Bausch Health Companies and Radius Health, Inc.
Dr. von Eschenbach received his B.S. in biology from St. Joseph's University and his M.D. in medicine from Georgetown University.
Member of the Nominating and Corporate Governance Committee
Member of the Science and Technology Committee
Job Titles:
- Director
- Member of the Audit Committee
- Member of the Compensation Committee
- Member of the Compensation Committee Member of the Science and Technology Committee
- Member of the Science and Technology Committee
- President and Chief Executive Officer of Trishula Therapeutics
Dr. Singhal has served as the President and Chief Executive Officer of Trishula Therapeutics, a biotechnology company, since January 2021.
Previously, from May 2019 to September 2020, Dr. Singhal served as President and Chief Executive Officer of Adicet Bio, a publicly-traded biotechnology company, and from September 2020 to February 2021, he served as an advisor to Adicet. Dr. Singhal also served as Vice President, Early Oncology Development, of AbbVie Inc., a publicly-traded pharmaceutical company, from January 2013 to March 2018. Dr. Singal is a member of the American Association of Cancer Research, which he joined in 2005, and a member of the American Society of Clinical Oncology, which he joined in 2007. Dr. Singhal has been a member of the board of directors of TriSalus since 2018.
Dr. Singhal received his B.Sc Honours degree in Biochemistry from Panjab University in India, his MBA in Business Administration from the University of Washington and his PhD in Biochemistry from Rutgers University.
Member of the Compensation Committee
Member of the Science and Technology Committee
Job Titles:
- Member of the Audit Committee
- Member of the Nominating and Corporate Governance Committee
- Member of the Audit Committee / Member of the Nominating and Corporate Governance Committee
David served as the Chief Financial Officer and director of MTAC's since September 2020. David was also the co-founder and Chief Executive Officer of MatlinPatterson Global Advisers LLC ("MatlinPatterson"), a distressed securities investment manager, which he co-founded in July 2002, through 2021.
David was also Chief Executive Officer of MatlinPatterson Asset Management L.P. and its operating joint venture affiliates that managed non-distressed credit strategies, from 2015 to 2018. In 2017, MatlinPatterson began winding down its investment activities and its various funds began to return the investment proceeds to their respective investors. In conjunction with this wind-down process and to protect their investors from foreign litigation, two of the MatlinPatterson funds (Matlin Global Opportunities Partners II L.P. and Matlin Global Opportunities Partners (Cayman) II L.P.) that had been unable to settle foreign litigation, filed, along with MatlinPatterson, voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in July 2021. Prior to forming MatlinPatterson, David was a Managing Director at Credit Suisse, and headed their Global Distressed Securities Group upon its inception in 1994. David was also a Managing Director and a founding partner of Merrion Group, L.P., an investment advisory firm, from 1988 to 1994.
He began his career as a securities analyst at Halcyon Investments from 1986 to 1988. Until its November 2022 sale, David also served on the board of directors of US Well Services Inc. (Nasdaq: USWS) (formerly Matlin & Partners Acquisition Corporation) and was Chief Executive Officer and Chairman of the company prior to its business combination with US Well Services LLC. He also serves on the boards of directors of Dermasensor, Inc. and Pristine Surgical LLC, which are medical device manufacturers. David has served on the board of directors of Clene, Inc. (Nasdaq: CLNN), a biopharmaceutical manufacturer, since December 2020, and has served as the Chairman of its Board of Directors since May 2021. Since 2020, he has served on the board of Traffk, LLC, an insurance-based data analytics company, and since July 2021, he has served on the board of Empyrean Neuroscience, a biotechnology company. Previously, he served on the board of directors of Flagstar Bank FSB, a federally charted savings bank, and Flagstar Bancorp, Inc. (NYSE: FBC), a savings and loan holding company from 2009 to May 2021, CalAtlantic Group, Inc. (NYSE: CAA), a U.S. homebuilder, from 2009 to 2018, Global Aviation Holdings, Inc., an air charter company, from 2006 to 2012, and Huntsman Corporation (NYSE: HUN), a U.S. chemicals manufacturer, between 2005 and 2007 and Orthosensor, Inc. until the sale of the company to Stryker Corporation in December 2020.
David holds a JD degree from the Law School of the University of California at Los Angeles and a BS in Economics from the Wharton School of the University of Pennsylvania.
Member of the Audit Committee
Member of the Nominating and Corporate Governance Committee
Job Titles:
- Medical Director
- Founder and Medical Director of National Vascular Physicians
- Scientific Advisory Board Member
Dr. Alexander Y. Kim is the Founder and Medical Director of National Vascular Physicians, an out-patient based endovascular and interventional radiology group. He previously served as the Chief of the Division of Interventional Radiology at Georgetown University Medical Center. His research interests include developing novel methods to augment patient outcomes from locoregional therapies.
Dr. Alex Kim is the Interventional Radiology Medical Director at TriSalus since October 2023 and serves on the Scientific Advisory Board.
Previously, Dr. Kim served as an advisor to TriSalus from 2014 - 2021, and the Consultant Director of Interventional Oncology Clinical Strategy for TriSalus from September 2021 to September 2023. He has also served as a consultant for several medical device companies. Dr. Kim has an active part-time outpatient interventional radiology practice in the Washington DC metropolitan area in a practice that he co-founded and serves as the Medical Director. Prior to opening his outpatient practice, he served as the Chief of Interventional Radiology at Georgetown University Hospital where he also was the residency program director.
Dr. Kim received his B.S. in Biochemistry from the University of Washington and his M.D. from Drexel followed by completion of a combined diagnostic and interventional radiology residency at Georgetown.
Job Titles:
- Member of the Compensation Committee
- Chief Strategic Innovation Officer at Insightec
- Member of the Compensation Committee Member of the Science and Technology Committee
- Member of the Science and Technology Committee
Dr. Arjun Desai has served as the Chief Strategic Innovation Officer at Insightec, a medical device company, since 2018.
Previously, from 2016 to 2018, Dr. Desai served as the Global Vice President and Chief Operating Officer of Johnson & Johnson Innovation, a company that collaborates with innovators to incorporate science into healthcare solutions. Additionally, Dr. Desai currently serves on the boards of directors of Obvius Robotics, Inc., Tympa Health TechnologiesLtd, Pathology Watch, Openwater Software, Inc., and Wesper.
Dr. Desai received his B.S. degree in Economics from the University of Oklahoma and his M.D. from the University of Miami. He also completed his residency and advanced training in Anesthesiology at Stanford University.
Member of the Compensation Committee
Member of the Science and Technology Committee
Job Titles:
- Chief Scientific and Manufacturing Officer
Dr. Bryan F. Cox has been the Chief Scientific and Manufacturing Officer at TriSalus since June 2020.
Previously, Dr. Cox served as the Chief Executive Officer of Nephraegis Therapeutics, a biotechnology company, since November 2018. Prior to joining TriSalus, Dr. Cox served as a Consultant for CoPharm Global Consulting, a boutique consultancy focuses on providing guidance for biotechnology companies, from May 2013 to June 2020. Prior to that, Dr. Cox served as the Director of Integrative Pharmacology for Abbott Laboratories, a multinational medical devices and health care company, from 1996 to 2013. Dr. Cox has served on the board of directors for Nephraegis Therapeutics since November 2018.
Dr. Cox received his B.S. in Biological Sciences from North Carolina University and his Ph.D. in Pharmacology from the University of Iowa.
Job Titles:
- Scientific Advisory Board Member
- Vice Chair of the Department of Radiation Oncology
Dr. Christopher Crane is a Vice Chair of the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) specializing in gastrointestinal cancers. Prior to joining MSKCC, he served as Program Director/Chief of the Gastrointestinal Section, and Program Director of the Residency and Fellowship training programs in the Department of Radiation Oncology at the University of Texas M. D. Anderson Cancer Center.
Christopher is leading several cancer clinical trials across the country. He is interested in the role of radiation dose escalation using novel technologies in the treatment of liver and pancreatic cancers. He has helped develop technologies that allow administration of higher doses of radiation in GI malignancies and states that technology such as image guidance has helped with the challenge of internal organ motion.
Christopher has been involved with the NCI-Gastrointestinal Steering Committee, NRG Oncology Group, ASTRO, ASCO, Locally advanced and Advanced Pancreatic Clinical Practice Guidelines and the Emeritus Scientific and Medical Advisory Board of PANCAN.
Job Titles:
- Assistant Professor of Radiology at Columbia University Medical Center
- Scientific Advisory Board Member
Dr. Divya Sridhar is Assistant Professor of Radiology at Columbia University Medical Center and Chief of Vascular and Interventional Radiology at Harlem Hospital Center. Divya earned her medical degree at the University of Miami School of Medicine. She completed internship at Memorial Sloan Kettering Cancer Center, residency training at the University of California, San Francisco, and fellowship training in Interventional Radiology at the Mount Sinai Hospital in New York City. Her interests include application of novel technology and techniques to advance minimally invasive image-guided transcatheter and percutaneous treatment of cancer and other conditions.
Job Titles:
- Director
- Scientific Advisory Board Member
Dr. Jordan Tasse is the director of interventional oncology and an associate professor of vascular and interventional radiology at Rush University Medical Center in Chicago, Illinois. His practice focuses on minimally invasive cancer treatments throughout the body including the liver, lung, pancreas and kidney. Jordan is currently involved in multiple clinical research projects including trans-arterial cancer therapies, ablative treatments and immunotherapy.
Job Titles:
- Associate Professor
- Scientific Advisory Board Member
Dr. Rahul Sheth is an Associate Professor in the Department of Interventional Radiology at MD Anderson. Rahul received his undergraduate degree in Chemistry and Physics at Harvard University and his MD degree through the Health Sciences and Technology program at Harvard Medical School. After a medicine internship at the University of Pittsburgh, Rahul returned to Boston and completed his residency training in diagnostic radiology as well as fellowship training in Interventional Radiology at Massachusetts General Hospital.
As a clinician-scientist, Rahul studies how locoregional therapies can have positive systemic ramifications for cancer patients. His research interests include optical molecular imaging, tumor microenvironmental factors affecting minimally invasive cancer therapies, photothermal ablation and cancer immunology.
Job Titles:
- Associate Professor of Medicine at Columbia University Irving Medical Center
- Scientific Advisory Board Member
Dr. Richard D. Carvajal is an Associate Professor of Medicine at Columbia University Irving Medical Center where he serves as both Director of Experimental Therapeutics and Director of the Melanoma Service within the Division of Hematology/Oncology. He serves as Co-Leader of the Precision Oncology and Systems Biology Program within the Herbert Irving Comprehensive Cancer Center.
Richard's research is focused on the development of novel therapies for patients with melanoma and other cancers, with the overall objective of controlling and curing these diseases. To achieve this goal, he has used our increasing knowledge of the underlying biology of cancer to rapidly integrate this knowledge, novel targeted and immunotherapeutic agents, and efficient trial design in order to improve the outcomes of cancer patients everywhere. Richard's melanoma research has included the study and treatment of uncommon clinical and molecular subsets of melanoma such as melanomas arising from the eye (uveal melanomas), from the mucosal surfaces of the body (mucosal melanomas), and from the palms of the hands, soles of the feet or under the fingernails (acral melanomas).
He has been the principal investigator or co-investigator of over 500 clinical trials, including a number of investigator-initiated, multi-center, Cancer Therapy Evaluation Program (CTEP) sponsored and industry-supported clinical trials. His research has been supported by the National Cancer Institute, the Food and Drug Administration, the Conquer Cancer Foundation, the Melanoma Research Alliance, the Melanoma Research Foundation and the Empire Clinical Research Investigator Program. He has authored or co-authored more than 200 peer-reviewed manuscripts, books, and book chapters.
In addition to Richard's work at Columbia University Irving Medical Center, he serves as the co-chair of the International Rare Cancer Initiative Uveal Melanoma working group, a joint initiative between the National Cancer Institute, the European Organization for Research and Treatment of Cancer, and the Cancer Research UK to enhance international collaboration in the conduct of clinical trials for uveal melanoma.
Job Titles:
- Scientific Advisory Board Member
Dr. Ripal Gandhi did his undergraduate studies at Northwestern University and Harvard University. He graduated summa cum laude (highest honors). He received his degree in medicine from Northwestern University Medical School, where he also graduated with honors. Following medical school, he completed a surgical internship at Cornell University Medical Center and New York Presbyterian Hospital. He completed his residency training and fellowship at UCLA Medical Center. Currently, he is an associate clinical professor at the University of South Florida School of Medicine and FIU Herbert Wertheim College of Medicine. Ripal regularly trains other physicians in various vascular/endovascular, interventional radiology, and interventional oncology techniques.
Because of his interest in discovering new therapies, Ripal also dedicated an entire year to biomedical research at the renowned Memorial Sloan-Kettering Cancer Center in New York. At Sloan-Kettering, he investigated chemoembolization and other minimally invasive therapies for liver cancer and other malignancies. He also served as a research fellow at the National Institutes of Health (NIH). He has published his findings in several scientific journals, including the Journal of Vascular and Interventional Radiology, Journal of Vascular Surgery, Vascular Medicine, Interventional Cardiology, and Journal of the American College of Surgeons. He also authored several textbook chapters and presented his research at national and international meetings.
Prior to joining Miami Cardiac & Vascular Institute, he was an international visiting scholar at Asan Medical Center/University of Ulsan Medical School in Seoul, South Korea. As an international scholar, he gave several lectures and furthered his expertise in innovative minimally invasive therapies.
Ripal is the recipient of multiple awards, including the American College of Physicians Certificate of Merit for Outstanding Performance in Medicine, America's Best Physicians, America's Most Honored Doctors, Compassionate Doctor Award, Leading Physicians of the World, and Top 100 Health Professionals Distinction Award. In addition, he was recently honored with the Patients' Choice Recognition Award, given to physicians most highly regarded by their patients. He is also a fellow of the Society for Vascular Medicine and a fellow of the Society of Interventional Radiology.
He is the co-author of the textbook Interventional Oncology which was recently published. In addition to being an expert in endovascular therapy and vascular disease, Dr. Gandhi is one of the interventional oncologists at Miami Cancer Institute and has expertise in minimally invasive therapies for cancer. He is a program director for the International Symposium on Endovascular Therapy (ISET) and Symposium on Clinical Interventional Oncology (CIO).
Job Titles:
- Medical Director
- Medical Director at TriSalus
Dr. Robert Knight has been the Medical Director at TriSalus since August 2023. In this position, he plays a central role in the execution of our SD-101 clinical trials and device focused studies. Dr. Knight also supports the design of clinical protocols in addition to data collection, reporting and interpretation.
Dr. Knight is board certified in internal medicine, hematology, and oncology. During his pharmaceutical career he participated in and led clinical trials in Clinical Development in phase I through phase III in both large and small companies. These include clinical programs that have led to Health Authority approvals in the US, EU, Australia, Japan, and China and include such agents as pamidronate (Aredia), zoledronate (Zometa), irinotecan (Camptosar), thalidomide (Thalomid), lenalidomide (Aredia), and enasidenib (IDHIFA). In addition, his experience includes leading CAR-T cell trials in hematologic and solid tumors, including studies with liver metastases using PEDD.
Dr. Knight received his B.S. degree from the United States Military Academy at West Point, N.Y. and his M.D. from the State University of New York Downstate (Brooklyn, N.Y.).
Job Titles:
- Medical Oncologist and Associate Professor, Director of the Uveal Melanoma Program
- Scientific Advisory Board Member
Dr. Sapna Patel is a medical oncologist and Associate Professor, Director of the Uveal Melanoma Program, and Melanoma Fellowship Program Director at the University of Texas MD Anderson Cancer Center in Houston, Texas specializing in uveal, cutaneous, and mucosal melanoma with one of the largest metastatic uveal melanoma practices in the world.
Sapna has led several investigator-initiated and multi-institutional clinical trials, including studies of targeted therapy, immunotherapy, T-cell therapy, and antibody-drug conjugates for uveal melanoma. Her lab work focuses on translational research, characterizing longitudinal molecular signatures in tumor samples from patients receiving treatment. She also leads several cutaneous melanoma projects with SWOG and serves as Melanoma Chair for SWOG. She has received intramural and extramural funding including NIH grants. Her goal is to develop effective therapies for adjuvant and metastatic settings, and to identify biomarkers to predict clinical benefit.
Job Titles:
- Clinical Assistant Professor at Stanford University Department of Radiology
Dr. Sirish Kishore is a Clinical Assistant Professor at Stanford University Department of Radiology and an Attending Interventional Radiologist within the Palo Alto Veterans Affairs Healthcare System. His interests lie in minimally invasive catheter-based and percutaneous techniques to improve the therapeutic index of cellular and immuno-oncology agents.
Job Titles:
- Assistant Professor of Radiology
- Scientific Advisory Board Member
Dr. Terence Gade is Assistant Professor of Radiology, Penn Presbyterian Medical Center, Attending, Hospital of the University of Pennsylvania, and Assistant Investigator, Abramson Cancer Research Institute. Terence co-founded the Penn Image-Guided Interventions (PIGI) Laboratory. The interests of the laboratory focus on translational research for the development of novel imaging approaches and advanced therapeutics.
Job Titles:
- Director for the Pancreaticobiliary Program at Virginia Mason Medical Center
- Scientific Advisory Board Member
Dr. Vincent J. Picozzi is Director for the Pancreaticobiliary Program at Virginia Mason Medical Center. A summa cum laude, Phi Beta Kappa graduate from Yale University, Vincent obtained his MD degree from Stanford University, did his internship and residency at Harvard University (Brigham and Women's Hospital) and fellowships in hematology and oncology again at Stanford. He also holds a Master's degree in Medical Management, Delta Omega, from Tulane University. Vincent was an instructor in hematology and oncology at Stanford for two years before joining Virginia Mason, where he has been for the past 36 years.
Vincent has one of the largest pancreaticobiliary oncology practices in the United States. He has received numerous accolades as a clinician, including designation as one of Seattle's Best Doctors and one of America's Top Cancer Doctors for the last fifteen consecutive years (2008-2022). He also directs an active, comprehensive clinical and translational research program in pancreaticobiliary cancer at Virginia Mason and has published nearly 200 papers and abstracts.
Vincent has educational committees for the GI Oncology Symposium and ASCO for non-colorectal cancers and served as Educational Chair for both in 2016. He has been a featured speaker at virtually every major clinical oncologic meeting in the United States, including ASCO (the American Society of Clinical Oncology), ASH (the American Society of Hematology), ASTRO (the American Society of Therapeutic Radiation Oncology), Digestive Diseases Week, AHPBA (The American Hepatopancreaticobiliary Association), ACOS (the American College of Surgeons), the Best of ASCO, the GI Oncology Symposium and the World Pancreas Symposium.
Vincent also has held a number of leadership positions with national and regional organizations, including ASCO, ASH, the American College of Surgeons Oncology Group (ACOSOG), the Pancreatic Cancer Action Network where he is a past chairman and current board member for the Scientific and Medical Advisory Board, the Pancreas Cancer Research Team (PCRT-Executive Committee) and the Providence Hospice of Seattle (Executive Board). He also has proudly served on the Executive Board of the Washington State Medical Oncology Society since its inception 30 years ago, twice serving as president. Recently, Vincent is the co-principal investigator and Clinical Trials Consortium chairman of the new Precision Promise Clinical Research Consortium sponsored by the Pancreatic Cancer Action Network.
Job Titles:
- Member of the Audit Committee
- Member of the Compensation Committee
- Chairman of Transition Bio, Inc
- Member of the Audit Committee / Member of the Compensation Committee
George Kelly Martin currently serves as Chairman of Transition Bio, Inc., a molecular condensates discovery company, a role which he has held since 2020, and as Vice Chairman of Ride Therapeutics, Inc., a molecular logistics company, a role which he has held since 2022. He has also served as Chairman of WaveBreak (formerly Wren Therapeutics, Inc.), a company that utilizes physical science and kinetics to create therapeutic solutions for protein misfolding diseases, since 2018.
Previously, George served as President and Chief Executive Officer of Radius Health, Inc., a bone and women's health company, from 2020 to 2022. Prior to that, George served as Chief Executive Officer of Novan, Inc., a development-stage dermatology company, from 2018 to 2020. Prior to joining Novan, Inc., George was the Chief Executive Officer of Malin Corporation PLC, a life sciences investment company, from 2015 to 2017. George also served as Chief Executive Officer of Elan Corporation plc, an Ireland-based neurodegeneration research and development company, from 2003 to 2013. George's business career started in finance and capital markets, having spent 21 years at Merrill Lynch & Co. Inc. At the time of his departure from Merrill Lynch in 2002, he was a member of the company's Executive Operating Committee and his tenure included leadership oversight of four global divisions (debt markets, international equities, Information Technology, and International Private Banking). While at Merrill Lynch, George served multi-year assignments in both Tokyo and London. He previously served on the boards of directors of Questcor Pharmaceuticals, Immunocore Holdings, plc, and Kymab Ltd.
George received his B.A. in Politics from Princeton University.
Member of the Audit Committee
Member of the Compensation Committee
Job Titles:
- Senior Vice President - Investor Relations and Treasurer
James Young has served as the Senior Vice President - Investor Relations and Treasurer of TriSalus since August 2023.
Previously, James served as President of J Young Consulting LLC, where he served as an Interim CFO and also provided finance organization optimization services for small to medium sized companies, primarily in the life sciences industry. Prior to that, he held numerous progressive financial leadership roles during a 33 year career at Abbott Laboratories, including Divisional Vice President and Controller of the Diagnostics Division and Divisional Vice President and Controller of the Established Pharmaceutical Division, located in Basel, Switzerland. James also served as the Vice President and Chief Ethics and Compliance Officer for Abbott from 2015 to 2021. Prior to his time at Abbott, he was a Senior Auditor at Ernst and Whinney.
James received his BBA in Accounting from St. Norbert College and is a Certified Public Accountant, State of Wisconsin.
Job Titles:
- Chief Regulatory Officer
- Chief Regulatory Officer at TriSalus
Jennifer Stevens has been the Chief Regulatory Officer at TriSalus since March 2022 and served as TriSalus' Senior Vice President of Regulatory Affairs from March 2021 to March 2022.
Previously, Jennifer held several progressive leadership roles with EMD Serono Inc., a division of Merck KGaA focused on biopharmaceuticals, from January 2016 through March 2021, including as Acting Head of US Oncology Hub - Regulatory Affairs. Previously, Jennifer was Regulatory Counsel for the U.S. Food and Drug Administration from July 2008 to December 2012. Earlier in her career, Jennifer was a practicing attorney at several global law firms, achieving partnership at Kirkland & Ellis LLP.
Jennifer received her B.A. in Political Sciences from the University of Illinois and her J.D. from George Washington University.
Job Titles:
- President, Commercial Operations
Jodi Devlin joined TriSalus in August 2023 and serves as President, Commercial Operations. Jodi has more than 30 years in the biotech and pharmaceutical industry. Her expertise includes prelaunch strategies, US and ex-US launches, medical affairs, marketing, sales, reimbursement, and patient advocacy. She has led multiple $B pharmaceutical launches.
At TriSalus, Jodi is leading the go-to-market strategy for the therapy and technology businesses. Her focus includes patient advocacy, medical affairs, health economics, and commercial execution.
Prior to joining TriSalus, Jodi served as CEO of AltaThera Pharmaceuticals, a specialized, hospital pharmaceutical company. Jodi executed a turnaround where she raised funding, obtained a new FDA indication, built a commercial and clinical team, completed two new clinical trials, and significantly accelerated revenue. In addition, Jodi spent 21 years at Abbott/AbbVie where she held leadership roles in pipeline planning, global launches, and management of numerous commercial organizations. Jodi's experience spans biotech start-ups and Fortune 500 companies. She currently serves as Chairman of the Board at Fitabeo Therapeutics.
Before her time in the biotech industry, Jodi worked as a hospital nurse in New York and Missouri. She earned a BS in Nursing from University of Oklahoma and a MBA from Washington University, Olin School of Business.
Job Titles:
- Director
- Member of the Audit Committee
- Member of the Nominating and Corporate Governance Committee
- Chief Executive Officer, and President of KMG Capital Partners LLC
- Member of the Audit Committee / Member of the Nominating and Corporate Governance Committee
Kerry has served as Partner, Chief Executive Officer, and President of KMG Capital Partners LLC, a boutique healthcare venture capital company, since April 2012. He also currently serves as Executive Chairman of Circuit Clinical, an integrated research organization, and Co-Chairman and Partner of HW Investment Partners, LLC, a venture capital firm that focuses on investing in healthcare companies, both positions which he has held since 2016.
Prior to joining KMG Capital Partners, Kerry served as Chief Executive Officer of Healthgrades, a healthcare information and services company, from 2000 to 2012, Chairman of Healthgrades from 2000 to 2010 and 2012 to 2013, and as President, Chief Executive Officer and Chairman of Specialty Care Network, a predecessor company to Healthgrades, from 1995 to 2000. Mr. Hicks has been a member of the board of directors of TriSalus since April 2021.
Kerry received his B.S. degree in Management and his MBA in Business Administration from Colorado State University.
Member of the Audit Committee
Member of the Nominating and Corporate Governance Committee
Job Titles:
- Associate Professor of Medicine and Medical Oncologist at Thomas Jefferson University Hospital
- Scientific Advisory Board Member
Dr. Marlana Orloff is an associate professor of medicine and medical oncologist at Thomas Jefferson University Hospital - Sidney Kimmel Cancer Center in Philadelphia, PA. Her clinical and research focus is on primary and advanced melanomas. Her main interest is in rare melanomas including uveal, conjunctival and mucosal melanoma.
Marlana's research is centered on investigating the epidemiology of uveal melanoma and discovery of novel therapies for primary and advanced uveal, conjunctival, mucosal and cutaneous melanoma. She works very closely with the team at Wills Eye Hospital to manage hundreds of patients with primary and metastatic ocular melanoma. Marlana is a member of a multidisciplinary team of medical oncologists, interventional radiologists, radiation oncologist and numerous other essential personnel that treats patients with metastatic uveal melanoma from all over the country. She is principal and co-investigator on a number of clinical trials enrolling patients with primary and advanced melanomas of all types.
Job Titles:
- Chief Executive Officer
- Director
- President
- Member of the Board of Directors for Kura Oncology
Mary Szela has nearly 35 years of experience driving growth and creating value for patients and investors in both the commercial and clinical pharmaceutical arenas.
Mary has served as CEO and President of TriSalus Life Sciences since January 2018. Prior to joining TriSalus, Mary served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she led the company through regulatory compliance and legal difficulties, ultimately orchestrating a successful merger and expansion of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company's revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus).
Previously, Mary held progressive leadership roles at Abbott Laboratories including President of the company's $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Senior Vice President for global strategic marketing and services.
Mary currently serves as a member of the Board of Directors for Kura Oncology, Prometheus Biosciences, Omega Therapeutics and Senda Biosciences. She received both her B.S. in Nursing and her MBA from the University of Illinois at Chicago.
Job Titles:
- Chairman of the Board
- Member of the Nominating and Corporate Governance Committee
- Chairman of the Board of Directors of Triomed AB
- Chairman of the Board of Directors of TriSalus
Member of the Nominating and Corporate Governance Committee
Mats Wahlström has served as Chairman of the board of directors of TriSalus since January 2017. Mats has also served as the Co-Chairman of HW Investment Partners, LLC since July 2016 and as Partner and Executive Chairman of KMG Capital Partners, LLC since April 2012, both investment funds focused on investments in the healthcare industry.
In addition, Mats has served as the Chairman of the board of directors of Triomed AB since October 2016, as the lead independent director of Coherus Biosciences, Inc., a public biotech company, since January 2012 and as Chairman of Caduceus Medical Holdings, Inc. since August 2010. Mats has served on the boards of directors of Alteco Medical AB since October 2012, Circuit Clinical Solutions, Inc. since July 2016 and PCI | HealthDev since August 2010. He served as a director of Health Grades, Inc. a Nasdaq-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010, as a director of Getinge AB, a Swedish Stock Exchange-listed medical device company, from March 2012 to March 2017, and as a director of Zynex Inc. an over-the-counter medical device manufacturer, from October 2010 through January 2014. From January 2004 to December 2009, Mats served as co-CEO of Fresenius Medical Care North America and a member of the management board at Fresenius Medical Care AG & Co. KGaA. From November 2002 to December 2009, Mats served as President and Chief Executive Officer of Fresenius Medical Services. Prior to that, Mats held various positions at Gambro AB in Sweden from January 1983 to February 2000, including President of Gambro North America and Chief Executive Officer of Gambro Healthcare Inc. as well as Chief Financial Officer of the Gambro Group.
Mats has a B.S. degree in Economics and Business Administration from the University of Lund, Sweden.
Job Titles:
- Senior Vice President Corporate Development and Strategy
Dr. Richard Marshak has been the Senior Vice President, Corporate Development and Strategy at TriSalus since June 2022.
Previously, Dr. Marshak was Managing Principal of LF Consulting, a consulting firm for biotechnology companies, from June 2013 to June 2022. Dr. Marshak also co-founded Nephraegis Therapeutics, a biotechnology company, in September 2018 and served as its Chief Business Officer. Previously, Dr. Marshak served as the Chief Executive Officer of Mount Tam Biotechnologies from May 2016 to October 2019. Prior to these roles, Dr. Marshak held several progressive leadership roles in Abbott Laboratories, a multinational medical devices and health care company, from 1999 to 2013, culminating as the Head of Global Strategic Pricing. Dr. Marshak has served on the board of directors of Nephraegis Therapeutics since August 2018 and previously served on the board of Mount Tam Biotechnologies from May 2016 to October 2019.
Dr. Marshak received his B.A. in Psychology and VMD in Veterinary Medicine from the University of Pennsylvania, and his MBA from the University of Chicago.
Job Titles:
- Chief Financial Officer
- Director
- CFO of TriSalus
Sean Murphy has served as CFO of TriSalus since June 2022. Sean has also been a director of TriSalus since August 2020 and served as the chairman of the audit committee from August 2020 through June 2022.
Previously, Sean served as Executive Vice President at Malin PLC, a publicly listed company investing in life sciences companies, from April 2016 through June 2021. Sean was a senior advisor at Evercore, an independent investment banking advisory firm, from August 2011 to June 2018. Prior to that, he held numerous positions over a 30-year career with Abbott Laboratories, a multinational medical devices and health care company, culminating as Vice President of Business Development and Licensing. Sean has had extensive Board experience as well. He currently serves on the boards of directors of Immucor, Xenex, and Prenosis. In addition, Sean previously served on the public company board of directors of Radius Health, where he sat on the audit committee, and Poseida, where he was a member of the compensation and governance committee.
Sean received his BBA in Finance and Accounting from Western Illinois University and his M.S. in Finance from University of Illinois. He is a Certified Public Accountant, State of Illinois.
Job Titles:
- Chief Medical Officer at TriSalus
- Chief Medical Officer, Scientific Advisory Board Chairman
Dr. Steven Katz has been the Chief Medical Officer at TriSalus since September 2020 and is Chairman of the Scientific Advisory Board, which includes leadership of TriSalus' Translational Immunotherapy Laboratory.
Previously, Dr. Katz served as an advisor to TriSalus from June 2014 to August 2020, and Chief Medical Advisor from January 2019 to August 2020. Since 2016, Dr. Katz has also served as a consultant for several companies developing cell therapies for solid tumors. In Dr. Katz's academic work, he is an Associate Professor of Surgery at Brown University and has been with Brown Surgical Associates in a part-time role since February 2022. From 2009-2021, Dr. Katz led the creation of a solid tumor immunotherapy program at CharterCare Health Partners, serving as the Director of the Office of Therapeutic Development and Complex Surgical Oncology Program Director during that time. While at CharterCare, he led a translational immunotherapy laboratory focused on immunosuppression and immunotherapy development, while serving as principal investigator for multiple immunotherapy trials which integrated novel delivery approaches.
Dr. Katz received his B.A. in Government & Biochemistry from Wesleyan University and his M.D. from New York University, followed by completion of a general surgery residency at New York University. He completed Immunology Research and Surgical Oncology fellowships at the Memorial Sloan-Kettering Cancer Center.
Dr. Steven Katz, MD, had operated on thousands of cancer patients and studied liver immune cells for nearly two decades. After years of clinical work and research, he was seeking answers to a fundamental question: How can we help more patients with liver and pancreatic tumors benefit from immunotherapy?
At the time, our company had been developing and commercializing an innovative new device technology and approach to administering therapeutics called Pressure-Enabled Drug Delivery™ (PEDD™). Dr. Katz saw its potential for use in liver tumors, and he led a phase 1 clinical trial using our PEDD approach to administer cell therapy. 1 The clinical results were promising, and Dr. Katz joined us as our CMO.
Job Titles:
- Scientific Advisory Board Member
A Professor of Hepatopancreatobiliary Surgical Oncology at the University of Washington and the Fred Hutchinson Cancer Center, Dr. Venu G. Pillarisetty treats patients with pancreatic cancer and other diseases involving the pancreas. He attended Columbia University College of Physicians and Surgeons, did his General Surgery residency at the University of Massachusetts, and completed fellowships in Tumor Immunology and Surgical Oncology at Memorial Sloan-Kettering Cancer Center prior to joining the faculty at the University of Washington.
Funded by the NIH, the DoD, and several industry partnerships, Venu's research laboratory work using cultured slices of fresh human tumors has revealed unique targetable aspects of tumor immunobiology. As a clinical trialist, he is actively working to translate his laboratory findings to patient care through NIH cooperative group studies.